CD6, CD6 molecule, 923

N. diseases: 216; N. variants: 8
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Precursor B-cell lymphoblastic leukemia
0.080 GeneticVariation disease BEFREE CASC15 is a conserved lncRNA that was upregulated in pediatric B-acute lymphoblastic leukemia (B-ALL) with t (12; 21) as well as pediatric acute myeloid leukemia (AML) with t (8; 21), both of which are associated with relatively better prognosis. 28724437 2017
Precursor B-cell lymphoblastic leukemia
0.080 GeneticVariation disease BEFREE The t(12;21) translocation is the most common translocation in childhood B-precursor ALL. 19264230 2009
Precursor B-cell lymphoblastic leukemia
0.080 Biomarker disease BEFREE Impaired differentiation is prominently observed in the pro-B-cell compartment, resulting in an proportional increase in early progenitors in vivo, consistent with the t(12;21) ALL phenotype. 16044150 2005
Precursor B-cell lymphoblastic leukemia
0.080 GeneticVariation disease BEFREE TEL is frequently disrupted by chromosomal translocations such as the t(12;21), which is associated with nearly one-fourth of pediatric B cell acute lymphoblastic leukemia. 12626745 2003
Precursor B-cell lymphoblastic leukemia
0.080 GeneticVariation disease BEFREE Therefore, we conclude that the TEL-AML1 RQ-PCR can, in principle, replace Ig/TCR RQ-PCR in B-precursor ALL with t(12;21). 11841400 2002
Precursor B-cell lymphoblastic leukemia
0.080 GeneticVariation disease BEFREE The TEL-AML1 fusion which results from the t(12;21) rearrangement in childhood B-precursor acute lymphoblastic leukaemia (B-precursor ALL) is often accompanied by loss of the untranslocated TEL allele. 11426627 2000
Precursor B-cell lymphoblastic leukemia
0.080 GeneticVariation disease BEFREE We conclude that childhood precursor B-ALL carrying the t(12;21) translocation display characteristic phenotypic features which could provide a rapid, simple, sensitive and specific screening method to select for those cases that should undergo confirmatory molecular analysis. 10914546 2000
Precursor B-cell lymphoblastic leukemia
0.080 Biomarker disease BEFREE Since the ider(21) is cytogenetically indistinguishable from i(21)(q10) and idic(21)(p11), changes associated with similar clinical features as the t(12;21), i.e. pre-B-cell ALL and age 1-10 years, we suggest that all ALL displaying these changes should be tested for ETV6/CBFA2 fusion transcript. 9233588 1997